351003-62-8Relevant articles and documents
PHOSPHODIESTERASE INHIBITORS AND USE
-
Paragraph 0112; 0181, (2021/04/02)
The invention provides compounds that may inhibits to ENPP1, and are accordingly useful for treatment disorders related to ENPP1. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent disorders related to ENPP1.
SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS
-
Page/Page column 75; 76, (2008/12/06)
-
Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping
Richardson, Christine M.,Nunns, Claire L.,Williamson, Douglas S.,Parratt, Martin J.,Dokurno, Pawel,Howes, Rob,Borgognoni, Jenifer,Drysdale, Martin J.,Finch, Harry,Hubbard, Roderick E.,Jackson, Philip S.,Kierstan, Peter,Lentzen, Georg,Moore, Jonathan D.,Murray, James B.,Simmonite, Heather,Surgenor, Allan E.,Torrance, Christopher J.
, p. 3880 - 3885 (2008/02/08)
Virtual screening against a pCDK2/cyclin A crystal structure led to the identification of a potent and novel CDK2 inhibitor, which exhibited an unusual mode of interaction with the kinase binding motif. With the aid of X-ray crystallography and modelling,